Evidence map›Paper›PMID 11602024›Full record

ArticleBMC biotechnology2001

A surrogate-based approach for post-genomic partner identification.

R C Pillutla, K Hsiao, R Brissette, P S Eder, T Giordano, P W Fletcher, M Lennick, A J Blume, N I Goldstein

Open access · goldAbstract read
In one paragraph

Article in BMC biotechnology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

R C PillutlaDGI BioTechnologies, Inc, Edison NJ, USA. pillutla@dgibt.com
K Hsiao
R Brissette
P S Eder
T Giordano
P W Fletcher
M Lennick
A J Blume
N I Goldstein
Message Pharmaceuticals (United States) · USCGIAR · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundModern drug discovery is concerned with identification and validation of novel protein targets from among the 30,000 genes or more postulated to be present in the human genome. While protein-protein interactions may be central to many disease indications, it has been difficult to identify new chemical entities capable of regulating these interactions as either agonists or antagonists.

resultsIn this paper, we show that peptide complements (or surrogates) derived from highly diverse random phage display libraries can be used for the identification of the expected natural biological partners for protein and non-protein targets. Our examples include surrogates isolated against both an extracellular secreted protein (TNFbeta) and intracellular disease related mRNAs. In each case, surrogates binding to these targets were obtained and found to contain partner information embedded in their amino acid sequences. Furthermore, this information was able to identify the correct biological partners from large human genome databases by rapid and integrated computer based searches.

conclusionsModified versions of these surrogates should provide agents capable of modifying the activity of these targets and enable one to study their involvement in specific biological processes as a means of target validation for downstream drug discovery.

Indexed as

GenomicsPeptide LibraryComputational BiologyDrug Evaluation, PreclinicalGenome, HumanHumansLymphotoxin-alphaProtein BindingProteinsReproducibility of ResultsRNA, MessengerSubstrate SpecificityLymphotoxin-alphaPeptide LibraryProteinsRNA, Messenger

Identifiers

PMID11602024
PMCPMC57814
OpenAlexW2114588239

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.